Vimta Labs FY26 Revenue Rises 19.5%; Dividend Declared
Vimta Labs reported a 19.5% YoY increase in FY26 total income to ₹4,163 Mn, with Q4 income reaching ₹1,120 Mn. The Board recommended a ₹2 per share dividend and approved the reappointment of Dr. S. P. Vasireddi as Executive Chairman for five years, along with the incorporation of a US subsidiary.
*this image is generated using AI for illustrative purposes only.
Vimta Labs Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The company reported total income of ₹4,163 Mn for FY26, up 19.5% year-on-year from ₹3,482 Mn, driven by strong growth in revenue from operations. For Q4 FY26, total income rose 16.6% YoY to ₹1,120 Mn, reflecting sustained business momentum across the year. The Managing Director attributed the performance to the exceptional execution of the Pharma and Food divisions.
Financial Performance Overview
The company's revenue from operations for FY26 reached ₹4,073 Mn, compared to ₹3,440 Mn in the prior year. On a quarterly basis, Q4 FY26 revenue from operations stood at ₹1,092 Mn. The following table presents a detailed breakdown of the company's financial performance:
| Particulars (₹ Mn) | Q4 FY26 | Q3 FY26 | QoQ (%) | Q4 FY25 | YoY (%) | FY26 | FY25 | YoY (%) |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,092 | 986 | — | 944 | — | 4,073 | 3,440 | — |
| Other Income | 28 | 18 | — | 16 | — | 90 | 42 | — |
| Total Income | 1,120 | 1,005 | 11.5% | 961 | 16.6% | 4,163 | 3,482 | 19.5% |
| Material and Testing Costs | 224 | 193 | — | 182 | — | 807 | 710 | — |
| Employee Benefits Expense | 296 | 284 | — | 273 | — | 1,144 | 970 | — |
| Other Expenses | 178 | 166 | — | 160 | — | 706 | 536 | — |
| Total Expenses | 699 | 644 | — | 614 | — | 2,658 | 2,220 | — |
| EBITDA | 421 | 344 | 22.3% | 347 | 21.5% | 1,489 | 1,262 | 18.0% |
| EBITDA (%) | 37.6% | 34.3% | — | 36.1% | — | 35.8% | 36.2% | — |
| Finance Costs | 3 | 2 | — | 4 | — | 12 | 19 | — |
| Depreciation Expense | 128 | 109 | — | 92 | — | 438 | 353 | — |
| PBT | 290 | 234 | 24.3% | 250 | 16.1% | 1,040 | 890 | 16.8% |
| PBT (%) | 25.9% | 23.3% | — | 26.0% | — | 25.0% | 25.6% | — |
| Tax | 79 | 58 | — | 67 | — | 264 | 222 | — |
| PAT | 211 | 176 | 20.1% | 183 | 15.2% | 775 | 668 | 16.1% |
| PAT (%) | 18.9% | 17.5% | — | 19.1% | — | 18.6% | 19.2% | — |
| Basic EPS (INR) | 4.70 | 4.00 | 19.6% | 4.10 | 15.3% | 17.40 | 15.00 | 15.9% |
Share and Market Information
As of March 31, 2026, Vimta Labs had a market capitalisation of INR 1,701.01 Cr, with a free-float of 64.15% translating to a free-float market cap of INR 1,091.20 Cr. The company maintained a lean balance sheet with total debt of ₹33.3 Mn and cash and cash equivalents of ₹650.6 Mn. The total shares outstanding stood at 4,46,69,355, with a three-month average daily trading volume of 2,42,931.67 shares (INR 11.39 Cr).
| Share Information (as on March 31, 2026) | Details |
|---|---|
| Market Cap (INR Cr) | 1,701.01 |
| Free-Float (%) | 64.15% |
| Free-Float Market Cap (INR Cr) | 1,091.20 |
| Total Debt (₹ Mn) | 33.3 |
| Cash & Cash Equivalents (₹ Mn) | 650.6 |
| Shares Outstanding | 4,46,69,355 |
| 3M ADTV (Shares) | 2,42,931.67 |
| 3M ADTV (INR Cr) | 11.39 |
| Industry | TIC |
Board Decisions and Corporate Actions
The Board of Directors recommended a dividend of ₹2/- (Rupee Two only) per equity share of face value ₹2/- each for FY26, subject to shareholders' approval at the ensuing Annual General Meeting. The record date for the payment of dividend is fixed as June 18, 2026, and the dividend will be paid on or before July 8, 2026. The Board also approved the notice for the 36th Annual General Meeting, scheduled for Thursday, June 25, 2026.
Additionally, the Board recommended the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a term of five years effective July 1, 2026, to June 30, 2031, subject to shareholder approval. Dr. S. P. Vasireddi, the Founder of the company, has over four decades of experience and holds 51,97,050 equity shares. The Board also approved a proposal for the incorporation of a wholly owned subsidiary in the USA.
| Corporate Action | Details |
|---|---|
| Dividend per Share (₹) | 2.00 |
| Face Value per Share (₹) | 2.00 |
| Record Date | June 18, 2026 |
| Dividend Payment Date | On or before July 8, 2026 |
| Annual General Meeting | June 25, 2026 (36th AGM) |
| Executive Chairman Reappointment | Dr. S. P. Vasireddi, effective July 1, 2026 to June 30, 2031 |
| US Subsidiary | Wholly owned subsidiary incorporation approved |
Historical Stock Returns for Vimta Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.66% | +3.96% | +1.03% | -24.77% | -5.03% | +318.99% |
How will Vimta Labs' proposed US wholly owned subsidiary impact its revenue mix and margin profile over the next 2–3 years, given the competitive landscape of the American TIC market?
With depreciation rising sharply (24% YoY to ₹438 Mn), what major capital expenditure cycles are ahead for Vimta Labs, and could this compress PAT margins in FY27?
Given the family-led leadership structure with Dr. S. P. Vasireddi's reappointment and Ms. Harita Vasireddi as Managing Director, how might institutional investors and proxy advisory firms respond to the special resolution at the AGM?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
